mitomycin + tamoxifen

Mitomycin + tamoxifen is a combination of two pharmaceutical agents used primarily in the treatment of breast cancer. Mitomycin is an antineoplastic antibiotic that acts as an alkylating agent, cross-linking DNA strands and inhibiting DNA synthesis, leading to cell death. Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to its receptor, thereby blocking the growth-promoting effects of estrogen on breast cancer cells. This combination has been studied as part of adjuvant chemoendocrine therapy for stage II, estrogen receptor-positive breast cancer and other malignancies. However, clinical studies have reported increased risks when these drugs are combined—specifically higher incidences of anemia, thrombocytopenia, and hemolytic uremic syndrome (HUS), which can be fatal[1][2]. The use of this combination should be carefully monitored due to these potential toxic interactions.

Other names

mitomycin and tamoxifenmitomycin C plus tamoxifen